Tim Lugo
Stock Analyst at William Blair
(0.70)
# 2,934
Out of 4,479 analysts
23
Total ratings
26.67%
Success rate
-21.25%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $17.54 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $5.96 | +571.14% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $4.36 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $165.96 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $0.84 | - | 2 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.14 | - | 1 | Nov 13, 2023 | |
| EYEN Eyenovia | Initiates: Outperform | n/a | $0.74 | - | 1 | Nov 1, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $8.09 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $8.66 | - | 2 | Sep 20, 2023 | |
| VTGN VistaGen Therapeutics | Downgrades: Market Perform | n/a | $3.33 | - | 2 | Jul 22, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | n/a | $82.22 | - | 2 | Nov 22, 2021 | |
| SAGE Sage Therapeutics | Downgrades: Market Perform | n/a | $10.82 | - | 1 | Jun 16, 2021 | |
| AVIR Atea Pharmaceuticals | Initiates: Outperform | n/a | $3.23 | - | 1 | Nov 24, 2020 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $36.56 | - | 1 | Jan 8, 2020 | |
| AKTX Akari Therapeutics, | Upgrades: Outperform | n/a | $3.10 | - | 2 | Sep 22, 2017 | |
| OVID Ovid Therapeutics | Initiates: Outperform | n/a | $0.77 | - | 1 | May 30, 2017 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | n/a | $34.17 | - | 1 | May 30, 2017 |
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.54
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $5.96
Upside: +571.14%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.36
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $165.96
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.84
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.14
Upside: -
Eyenovia
Nov 1, 2023
Initiates: Outperform
Price Target: n/a
Current: $0.74
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.09
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.66
Upside: -
VistaGen Therapeutics
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.33
Upside: -
BioMarin Pharmaceutical
Nov 22, 2021
Upgrades: Outperform
Price Target: n/a
Current: $82.22
Upside: -
Sage Therapeutics
Jun 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $10.82
Upside: -
Atea Pharmaceuticals
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.23
Upside: -
Xenon Pharmaceuticals
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $36.56
Upside: -
Akari Therapeutics,
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $3.10
Upside: -
Ovid Therapeutics
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -
Biohaven Pharmaceutical Holding Company
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $34.17
Upside: -